Analytical Data
-
Gene name
CD79A
- Application
-
Alternative Names
CD79a; MB-1; Membrane-bound immunoglobulin-associated protein; B-cell antigen receptor complex-associated protein alpha chain; MB-1 membrane glycoprotein
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P11912
-
Expression Region
His36~Gly219
-
Molecular Weight
24kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CD79A is a crucial component of the B-cell receptor (BCR) complex, playing a vital role in B-cell activation and signaling. It is a transmembrane protein that, along with its partner CD79B, forms a heterodimer essential for the proper functioning of the BCR in immune responses. The importance of CD79A in B-cell development and its involvement in various B-cell malignancies, including Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL), have prompted extensive research into its structure and function. Recombinant CD79A proteins are utilized in studies to dissect the molecular pathways involved in B-cell signaling and to explore potential therapeutic targets. By producing CD79A as a recombinant protein, researchers can investigate its interactions with other signaling molecules, assess its role in immune responses, and evaluate its potential as a biomarker for disease progression. Furthermore, the generation of antibodies against CD79A can facilitate the development of targeted therapies for B-cell disorders, enhancing treatment efficacy while minimizing off-target effects. Overall, the study of recombinant CD79A is pivotal for understanding B-cell biology and could pave the way for novel interventions in B-cell-related diseases.
